Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. MU
5. SPY
6. ACN
7. NVDA
8. BLZE
9. IBM
10. PRIM

Go back to Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1110.73 +8.65 (0.78%)
Previous Close $1102.08    52 Week High $88.16 
Open $1117.00    52 Week Low $67.88 
Day High $1122.02    P/E 257.11 
Day Low $1079.22    EPS $4.32 
Volume 2,135,503